Results 231 to 240 of about 4,110,454 (393)

2. Linked Totems [PDF]

, 1909
A. Lang
openalex   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Non-Classical H1-like PARP1 Binding to Chromatosome. [PDF]

Cells
Koshkina D, Maluchenko N, Nilov D, Lyubitelev A, Korovina A, Pushkarev S, Armeev G, Kirpichnikov M, Studitsky V, Feofanov A.   +9 more
europepmc   +1 more source

Erratum: 3. Linked Totems in British New Guinea. [PDF]

, 1909
C. G. S.
openalex   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Functionalization of lipid nanoemulsions with humanized antibodies using plug-and-play cholesterol anchor for targeting cancer cells. [PDF]

Nanoscale Adv
Boide-Trujillo VJ, Mittelheisser V, Liu F, Lefebvre O, Andreiuk B, Anton N, Goetz JG, Klymchenko AS.   +7 more
europepmc   +1 more source

Acid-linked Functions of Intermediates in Oxidative Phosphorylation

, 1959
Britton Chance, H. Russell Conrad
openalex   +1 more source

Some Recently Discovered Silurian Fish Remains. A Link in the Chain of Organic Evolution 1 [PDF]

, 1900
G. B. H
openalex   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Polymer Nanomedicines with pH-Triggered Pirarubicin Release: Revealing the Role of Carrier Hydrophilicity and Release Kinetics in Anticancer Performance. [PDF]

Biomacromolecules
Pytlíková S, Jiang B, Woldřichová L, Kotalík K, Androvič L, Gao S, Šubr V, Rumlerová A, Pola R, Podhorská N, Filipová M, Zhang M, Pechar M, Fang J, Laga R, Etrych T.   +15 more
europepmc   +1 more source